![4-[(4-Methylpiperazin-1-yl)methyl]benzoic asid dihydrochloride CAS NO.106261-49-8 Imaj Prezantasyon](http://cdn.globalso.com/shlzpharma/106261-49-8-1.jpg)
![4-[(4-Methylpiperazin-1-yl)methyl]benzoik asid dihydrochloride CAS NO.106261-49-8](http://cdn.globalso.com/shlzpharma/106261-49-8-2.jpg)
4-[(4-Methylpiperazin-1-yl)methyl]benzoik asid dihydrochloride CAS NO.106261-49-8
| Non | 4-[(4-Methylpiperazin-1-yl)methyl]benzoik asid dihydrochloride | ||
| CAS NO. | 106261-49-8 | ||
| Fòmil molekilè | C13H20Cl2N2O2 | Pwa molekilè | 307.22 |
| MDL No. | MFCD08060469 | EINECS | 600-728-4 |
| MP | 305-307 °C | BP | NA |
| Dansite | NA | Endèks refraktif | NA |
| FP | NA | Kondisyon depo | Atmosfè inaktif, Tanperati chanm |
|
| |||
| Aparans | poud kristal blan ak blan | ||
| Pite | 98% | ||
| Aplikasyon | Imatinib entèmedyè | ||
| Kapasite Pwovizyon pou | 4-[(4-Methylpiperazin-1-yl)methyl]benzoic asid dihydrochloride CAS NO.106261-49-8 se pwodwi regilyèman pwodiksyon nou an, si ou bezwen ti echantiyon oswa yon gwo kago ki gen plis pase tonnage, konpayi nou an ka bay li. fòmèlman | ||
| Si w enterese nan 4-[(4-Methylpiperazin-1-yl)methyl]benzoic asid dihydrochloride CAS NO.106261-49-8, santi w lib kontakte nou tanpri, epi nou pral ba ou pi bon kalite pwodwi yo, pri rezonab ak pi bon sèvis, espere koperasyon nou an. | |
| | |
| Nimewo telefòn | +86 139 6251 3054 +86 136 2174 3828 |
Pwodwi yo ki nan lis pa konpayi an enplike patant, ki se sèlman pou rechèch ak devlopman epi yo pa pou vann;pwodwi kontwole yo pral vann an konfòmite strik ak lwa Chinwa ak lwa yo nan peyi kote yo achte, ak tout pwodwi yo pa apwopriye pou itilizasyon imen.Si yo vann, yo pral konstitye peyi vyolasyon patant, tout risk korespondan yo pral pote pa achtè a.
![5-[4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6-yl]-2-furaldehyde CAS NO.231278-84-5](http://cdn.globalso.com/shlzpharma/117.png)
![(7a,17b)-7-[9-[(4,4,5,5,5-Pentafluoropentyl)Thio]Nonyl]-Estra-1,3,5(10)-Triene-3,17-Diol 17- Acetate CAS NO.875573-69-6](http://cdn.globalso.com/shlzpharma/127.png)
